<DOC>
	<DOC>NCT02537834</DOC>
	<brief_summary>An open-label, multicenter study to evaluate 52-week long-term safety, tolerability and efficacy of Tofogliflozin with GLP-1 analogue treatment in type 2 diabetes mellitus.</brief_summary>
	<brief_title>Tofogliflozin GLP-1 Analogue Combination Trial</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>The subject aged from 20 to 75 years old with type 2 diabetes mellitus(T2DM) The subject with hemoglobin A1c ≧7.5% ＜10.5 % The subject who has been receiving a stable dose and regimen of GLP1 analogue over 8 weeks before Screening test The subject with type 1 diabetes mellitus The subject with Pregnancy or lactation The subject with Fasting Plasma Glucose ≧ 270 mg/dl The subject with history of metabolic acidosis, including diabetic ketoacidosis ,within 1 year prior to screening The subject with myocardial infarction, stroke, or heart failure requiring hospitalization or drug or alcohol abuse within the previous 6 months The subject with serum creatinine level greater than 2.0 mg/dL for men and 1.5 mg/dL for women The subject with aspartate aminotransferase(AST) or alanine aminotransferase(ALT) ≧ 2.5 times the upper limit of the reference range at the central laboratory test facility The subject has received treatment with another investigational product or nonapproved drug 3 months before screening The subject with history of Tofogliflozin therapy The subject with estimated glomerular filtration rate of &lt;30 mL/min/1.73 m^2 The subject who frequently experiencing orthostatic hypotension The subject systolic blood pressure of ≧ 180 or mmHg of diastolic blood pressure of ≧ 100 mmHg The subject required a change in the dosing regiment for the following drugs within 4 weeks before screening : Lipidlowering drug , Antihypertensive drug, Thyroid hormone drug , Uric acid lowering drug</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>